Markets
BioNexus Gene Lab Corp. (BGLC)
BGLCNASDAQ-CMMedical Specialities
$0.8200
-0.0099 (-1.19%) today
Closed, Nov 10, 4:00 PM ET
-1.19% 1D
- Market cap
- $2.47m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8199 to $5.41
- Average volume
- 7,107
- Previous close
- $0.8299
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $2.54m | $484.0k | $23.0k | $76.0k |
| Gross profit | $378.0k | -$4,000 | -$1,000 | $13.0k |
| Operating income | -$810.0k | -$1.06m | -$598.0k | -$403.0k |
| Net income | -$667.0k | -$1.05m | -$544.0k | -$286.0k |
Last four quarters: revenue $3.13m, margin -81.6%, free cash flow –
News
2 latestThe company
BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-CM
- Region
- Asia
- Website
- bionexusgenelab.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.